Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.

Pharmacology research & perspectives - 1 Jun 2024

Jaramillo-Valverde Luis, Levano Kelly S, Tarazona David D, Capristano Silvia, Sanchez Cesar, Poterico Julio A, Tarazona-Santos Eduardo, Guio Heinner

Abstract excerpt

In Peru, 29 292 people were diagnosed with tuberculosis in 2022. Although tuberculosis treatments are effective, 3.4%-13% are associated with significant adverse drug reactions, with drug-induced liver injury (DILI) considered the most predominant. Among the first-line antituberculosis drugs, isoniazid is the main drug responsible for the appearance of DILI. In liver, isoniazid (INH) is metabolized by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to Cytochrome P-450 CYP2E1

Share to Indians, South American

Share to Isoniazid

Share to Racial Groups

Source

Open in PubMed Open full text

Identifiers

PMID: 38666760
DOI: 10.1002/prp2.1179
PMCID: PMC11047445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.PMID 38666760Read ↗

Pharmacogenetic Study of Anti-TB Drugs in the Native Ancestry Peruvian Population.Semantic proximity Read ↗

Allelic and Genotypic Frequencies of NAT2, CYP2E1 and AADAC genes in a cohort of Peruvian Tuberculosis PatientsSemantic proximity Read ↗

NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.Semantic proximity Read ↗

GSTT1/GSTM1 Genotype and Anti-Tuberculosis Drug-Induced Hepatotoxicity in Peruvian Patients.Semantic proximity Read ↗

Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.Semantic proximity Read ↗

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohortSemantic proximity Read ↗

Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.Semantic proximity Read ↗

Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study.Semantic proximity Read ↗

Higher native Peruvian genetic ancestry proportion is associated with tuberculosis progression riskSemantic proximity Read ↗

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.